AIM
CRDF icon

Acrospire Investment Management’s Cardiff Oncology CRDF Stock Holding History

Acrospire Investment Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-58
Closed -$9K – 2248
2016
Q4 		$9K Buy
58
+48
+480% +$11.2K ﹤0.01% 1965
2016
Q3 		$3K Buy
+10
New +$3.65K ﹤0.01% 1877

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Acrospire Investment Management's CRDF Position: Q1 2017 in Review

Acrospire Investment Management sold out of Cardiff Oncology (CRDF) in Q1 2017, closing a stake of 58 shares — an estimated $9K sold.

Acrospire Investment Management first reported a position in CRDF in Q3 2016 and held it in 2 quarters. The position peaked at $9K in Q4 2016. 62 funds tracked by Wall St. Rank hold CRDF as of Q1 2017.

  • Acrospire Investment Management reported no remaining Cardiff Oncology position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 58 Cardiff Oncology shares in Q1 2017, an estimated $9K.
  • Acrospire Investment Management first reported a position in Cardiff Oncology in Q3 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Cardiff Oncology position peaked at $9K in Q4 2016.
  • 62 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.